Bloomage BioTechnology (688363) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was RMB 829.41 million, down 23.06% year-over-year; net profit attributable to shareholders was RMB 64.65 million, down 36.55% year-over-year.

• Decline in profit mainly due to lower revenue from skin science innovation and transformation business and strategic investments for future growth.

• Operating cash flow turned positive to RMB 130.96 million, reflecting improved operational efficiency and cost control.

• Company is undergoing strategic restructuring, focusing on synthetic biology, AI integration, and high-quality development.

Financial highlights

• Operating income: RMB 829.41 million, down 23.06% year-over-year.

• Net profit attributable to shareholders: RMB 64.65 million, down 36.55% year-over-year.

• Operating cash flow: RMB 130.96 million, a significant improvement from negative RMB 22.98 million last year.

• Basic and diluted EPS: RMB 0.14, down 33.33% year-over-year.

• R&D investment: RMB 85.79 million, accounting for 10.34% of revenue.

Outlook and guidance

• Company aims to drive growth through synthetic biology and AI, focusing on anti-aging and tissue regeneration.

• Strategic restructuring expected to yield higher quality growth and improved product logic.

• Anticipates new growth cycle as production capacity and brand/product upgrades are completed.